Trifluridine/tipiracil plus bevacizumab prolongs survival in refractory colorectal cancer
Continued Avastin Extends Survival After 1st Progression in Colorectal Cancer - CancerConnect
La trifluridine plus le tipiracil et le bévacizumab est une nouvelle norme de soins pour le cancer colorectal métastatique réfractaire
How does chemo fit into my treatment plan? - Colontown University
Third-Line Treatment for Metastatic Colorectal Cancer | LONSURF® (trifluridine and tipiracil) tablets
La FDA approuve Lonsurf plus bevacizumab pour le traitement du cancer colorectal métastatique
How does chemo fit into my treatment plan? - Colontown University
Lonsurf® Treatment for Colorectal Cancer - CancerConnect
First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study | British Journal of Cancer
Servier et Taiho Oncology présentent des données sur la survie globale de trifluridine/tipiracil (LONSURF®) en association avec le bevacizumab chez des patients atteints d'un cancer colorectal métastatique réfractaire... | Business Wire
LONSURF® (trifluridine and tipiracil) tablets Efficacy | Previously Treated Metastatic GEJ and Gastric Cancer Treatment
Combination extends OS in metastatic colorectal cancer
NCCN® Guidelines for Metastatic Colon Cancer Treatment
NCCN® Guidelines for Metastatic Colon Cancer Treatment
Adding Avastin to Lonsurf Improved Outcomes in Pretreated Colorectal Cancer
Precision treatment in colorectal cancer: Now and the future - Yau - 2019 - JGH Open - Wiley Online Library
Trifluridine/Tipiracil in Previously Treated Metastatic Colorectal Cancer - The ASCO Post
Lonsurf (Trifluridine plus Tipiracil): A New Oral Treatment Approved for Patients with Metastatic Colorectal Cancer
These highlights do not include all the information needed to use LONSURF safely and effectively. See full prescribing information for LONSURF. LONSURF (trifluridine and tipiracil) tablets, for oral use Initial U.S. Approval:
Current Oncology | Free Full-Text | A Systematic Review and Meta-Analysis of Trifluridine/Tipiracil plus Bevacizumab for the Treatment of Metastatic Colorectal Cancer: Evidence from Real-World Series
Servier : AMM européenne pour LONSURF en association au bevacizumab dans le cancer colorectal métastatique réfractaire | MyPharma Editions
TAS-102 plus bevacizumab: a new standard for metastatic colorectal cancer? - The Lancet Oncology